Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.36 |
| ▸ | ANPEP | P15144 | 3/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10142141 | 1.00 | SLC22A6 (0.41) | SLC22A6GABRR1LMNATDP1SMN1; SMN2 | |
| SCHEMBL19405330 | 1.00 | SLC22A6 (0.41) | SLC22A6GABRR1LMNATDP1SMN1; SMN2 | |
| SCHEMBL288510 | 0.88 | SLC22A6 (0.50) | SLC22A6GABRR1LMNATDP1SMN1; SMN2 | |
| SCHEMBL28799207 | 0.85 | SLC22A6 (0.47) | SLC22A6GABRR1LMNATDP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7372643 | 0.85 | SLC22A6 (0.47) | SLC22A6GABRR1LMNATDP1SMN1; SMN2 | |
| SCHEMBL6734053 | 0.85 | SLC22A6 (0.47) | SLC22A6GABRR1LMNATDP1SMN1; SMN2 | |
| Bromide SCHEMBL1086994 | 0.85 | ALOX15 (0.37) | LMNATDP1ALOX15BLMPMP22 | |
| Glutamic Acid SCHEMBL28162327 | 0.80 | GRM8 (0.64) | ALOX15BLMPMP22KMT2AENPEP | |
| Acetic Acid SCHEMBL2595033 | 0.80 | SLC22A6 (0.43) | SLC22A6GABRR1LMNATDP1SMN1; SMN2 | |
| Ornithine Aketoglutarate SCHEMBL28881960 | 0.79 | GSR (0.58) | ALOX15BLMPMP22KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024501-A1 | NEUROMODULATORY PEPTIDES | LACTOCORE, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| CN-116670151-A | Antibacterial cyclic peptides targeting acinetobacter and other gram negative pathogens | 犹他大学研究基金会 | 2023-08-29 | — | — | CN | claimed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | claimed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | claimed |
| EP-2499148-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2012-09-19 | — | — | EP | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | GENEFRONTIER CORPORATION (JP) | 2026-03-03 | — | — | US | disclosed |
| EP-3784807-B1 | SYNBIOTIC COMPOSITIONS | EVONIK OPERATIONS GMBH (DE) | 2025-06-04 | — | — | EP | disclosed |
| CN-104984319-B | TFPI inhibitors and methods of use | 武田药品工业株式会社 | 2025-05-09 | — | — | CN | disclosed |
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010127704-A1 | BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100173847-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | SLC22A6 2807/4885GABRR1 335/4885LMNA 2246/4885 |
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | SLC22A6 2158/4885GABRR1 4142/4885LMNA 1445/4885 |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | CXCL10, MLX, MICA | SLC22A6 1974/4885GABRR1 2488/4885LMNA 1808/4885 |
| US-20100173847-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, SERPINC1 | SLC22A6 2146/4885GABRR1 4010/4885LMNA 1394/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | SLC22A6 3858/4885GABRR1 631/4885LMNA 2799/4885 |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | KCNB1, KCNAB1, KCNMB1 | SLC22A6 3167/4885GABRR1 1181/4885LMNA 2161/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | SLC22A6 3858/4885GABRR1 631/4885LMNA 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.